In experimental rabbit meningitis, gemifloxacin penetrated inflamed meninges well (22 to 33%) and produced excellent bactericidal activity (change in log 10 [⌬log 10 ] CFU/ml/h, ؊0.68 ؎ 0.30 [mean and standard deviation]), even superior to that of the standard regimen of ceftriaxone plus vancomycin (؊0.49 ؎ 0.09 ⌬log 10 CFU/ml/h), in the treatment of meningitis due to a penicillin-resistant pneumococcal strain (MIC, 4 mg/liter). Even against a penicillin-and quinolone-resistant strain, gemifloxacin showed good bactericidal activity (؊0.48 ؎ 0.16 ⌬log 10 CFU/ml/h). The excellent antibacterial activity of gemifloxacin was also confirmed by time-kill assays over 8 h in vitro.
Before the emergence of penicillin-resistant pneumococci, penicillin was usually the first-line antibiotic in the treatment of pneumococcal infections. The global increase of resistant pneumococci has jeopardized the treatment of pneumococcal infections (3) . Additional resistance to cephalosporins has further limited therapeutic options for penicillin-resistant isolates. Despite the limitations of the actual therapeutic modalities, ␤-lactam antibiotics remain the first-line drugs for pneumococcal diseases, except when penetration into infected tissues is limited, as is the case in meningitis. At present, a combination of vancomycin and a cephalosporin is recommended for meningitis due to resistant strains (3, 10 ). An alternative regimen based on monotherapy would represent significant progress.
Especially due to its activity against many gram-positive microorganisms, including penicillin-resistant pneumococci, gemifloxacin, a new quinolone, is one of the most interesting can Little is known about the penetration of gemifloxacin into inflamed meninges. The aims of this study were to investigate the kinetics of gemifloxacin in the subarachnoid space and to test its bactericidal activity against pneumococci resistant to penicillin and to quinolones in the rabbit meningitis model. The standard regimen consisted of ceftriaxone combined with vancomycin.
Strains. The pneumococcal strain (WB4) was originally isolated from a patient with pneumonia at the University Hospital of Bern, Bern, Switzerland. The MICs (milligrams per liter) for this strain were as follows: penicillin, 4; ceftriaxone, 0.5; vancomycin, 0.12 to 0.25; trovafloxacin, 0.12; ciprofloxacin, 0.5; and gemifloxacin, 0.015. A quinolone-resistant strain was obtained by sequential exposure of parental strain WB4 to trovafloxacin. High-level resistance was conferred by point mutations in ParC (Ser793Phe) and in GyrA (Ser813Phe) (5).
The MICs (milligrams per liter) for this strain were as follows: penicillin, 4; ceftriaxone, 0.5; vancomycin, 0.12 to 0.25; trovafloxacin, 4; ciprofloxacin, 32; and gemifloxacin, 0.5.
Rabbit meningitis model. The meningitis model, originally described by Dacey and Sande (6), was slightly modified. The experimental protocol was accepted by the Veterinäramt des Kantons Bern. Young New Zealand White rabbits weighing 2 to 2.5 kg were anesthetized by intramuscular injections of ketamine (30 mg/kg of body weight) and xylazine (15 mg/kg) and were immobilized in stereotaxic frames for induction of meningitis and cerebrospinal fluid (CSF) samplings. An inoculum containing approximately 10 5 CFU of either a penicillin-resistant strain (WB4) or a penicillin-and quinolone-resistant pneumococcus of serotype 6 was directly injected into the cisterna magna. A long-acting anesthetic (ethylcarbamate-urethane, 3.5 g/rabbit) was injected subcutaneously, and animals were returned to their cages. Fourteen hours later, a catheter was introduced into the femoral artery for serum sampling, and the cisterna magna was punctured again for periodic CSF samplings before and 1, 2, 4, 6, and 8 h after initiation of therapy. Antibiotics were administered through a peripheral ear vein as bolus injections at the following concentrations: gemifloxacin, 15 mg/kg for the penicillin-resistant strain and 30 mg/kg for the quinolone-resistant strain; ceftriaxone, 125 mg/kg; and vancomycin, 20 mg/kg. Ceftriaxone and gemifloxacin were injected once at 0 h and vancomycin was injected at 0 and 4 h as described by Friedland et al. (7), Gerber et al. (9) , and Cottagnoud et al. (4) . Untreated controls received saline. All antibiotics and anesthetic drugs were commercially purchased, except for gemifloxacin, which was kindly provided by Glaxo SmithKline Company.
Bacterial titers were measured by using 10-fold serial dilutions of CSF samples plated on blood agar plates containing 5% sheep blood and incubated overnight at 37°C. In parallel, 20-l undiluted CSF samples were plated (limit of detection, 50 CFU/ml). A comparison between different dilutions of CSF was used to exclude significant carryover effects during therapy. The antimicrobial activities of the regimens during the 8-h treatment were calculated by linear regression analysis and expressed as a change in the log 10 (⌬log 10 ) CFU per milliliter per hour and as the killing rate over 8 h. A value of 1.7 (log 10 limit of detection) was assigned to the first sterile CSF sample, and a value of 0 was assigned to any following sterile sample. The results are expressed as means and standard deviations. Statistical significance was determined by the Newman-Keuls test.
Measurement of antibiotic levels in CSF. Antibiotic concentrations in CSF were determined by the agar diffusion method. Standard curves were determined for saline with 5% rabbit serum in order to mimic the CSF protein concentration (12) . Bacillus subtilis (ATCC 6633) was used as a test strain for gemifloxacin (14) . The intra-and interday variabilities of this method were less than 10%. The limit of detection for gemifloxacin was 0.05 mg/liter.
In vitro assays. The pneumococcal strains (penicillin-resistant strain WB4 and the quinolone-resistant strain) were grown in CϩY medium (11) to an optical density at 590 nm of 0.3 and then diluted 40-fold to 10 6 CFU/ml, corresponding to the CSF bacterial titer in rabbits before the initiation of therapy. Antibiotics were added at concentrations corresponding to 1, 5, and 10 times the MIC (the MICs were 0.015 and 0.5 mg/liter for the penicillin-resistant and the quinolone-resistant strains, respectively). Bacterial titers were determined at 0, 2, 4, 6, and 8 h by serial dilution of samples, plating on agar plates containing 5% sheep blood, and incubation at 37°C for 24 h. Experiments were performed in triplicate, and the results are expressed as means and standard deviations. Figure 1 shows the kinetics for gemifloxacin after a single dose of 15 mg/kg. The gemifloxacin concentration in serum peaked at a mean of 5.9 mg/liter and declined slowly to 0.45 mg/liter 8 h later. With 320 mg of gemifloxacin per os in healthy volunteers, an area under the curve (AUC) in serum over 24 h of 10.3 mg · h/liter was reached, comparable to the serum AUC from 0 to 8 h (AUC 0-8 ) of 12.2 mg · h/liter observed in rabbits, although the peak level in serum was higher in the animals (5.9 versus 2.3 mg/liter) (8) . The highest level in CSF was 0.7 mg/liter and decreased progressively to 0.12 mg/ liter by the end of the treatment period. CSF penetration of gemifloxacin was calculated by comparison of serum and CSF AUCs for each rabbit (Systat Software; SSPP Inc., Evanston, Ill.). In our rabbit model, the penetration of gemifloxacin into the subarachnoid space was about 22% Ϯ 6% after one injection of 15 mg of gemifloxacin/kg. The CSF drug concentration/ MIC ratios ranged between 46 and 8.
A higher dose of gemifloxacin (30 mg/kg) was chosen in order to maintain levels in CSF above the MIC (0.5 mg/liter for the quinolone-resistant strain) over the entire treatment period. The kinetics for 30 mg of gemifloxacin/kg are shown in Fig. 2 . In serum, gemifloxacin peaked at 12.2 mg/liter and declined to 2.35 mg/liter after 8 h. The serum AUC 0-8 was 41 mg · h/liter. The peak level in CSF was 2.5 mg/liter and the trough level was 0.45 mg/liter at 8 h. The CSF drug concentration/MIC ratios ranged between 5 and 0.9. After one injection of 30 mg/kg, the penetration into the CSF was 33% Ϯ 5%. The better CSF penetration at the higher dose (30 mg/kg) might be related to the drastic increase in the AUC 0-8 with a dose of 30 mg/kg (41 versus 12.2 mg · h/liter) in rabbits and might be due to an oversaturation of protein binding (protein binding of gemifloxacin in rabbits, 50 to 60%; Glaxo SmithKline Company, personal communication). Increasing the dose from 320 to 640 mg per os in humans led to only a doubling of the AUC (2). The doses of ceftriaxone and vancomycin used were standard doses that have been used in previous studies with the same model (4, 7, 9) and that correspond to high doses in humans (1, 13).
The killing rates for the different treatment groups are summarized in Table 1 . Gemifloxacin produced highly bactericidal activity and managed to sterilize the CSF of 7 out of 11 rabbits after 8 h. All animals in the gemifloxacin group survived. It is interesting that gemifloxacin monotherapy was significantly superior to the standard regimen of ceftriaxone combined with vancomycin for the penicillin-resistant strain. On the other hand, the standard regimen was slightly but not significantly superior to gemifloxacin monotherapy for the penicillin-and quinolone-resistant mutant.
In vitro, gemifloxacin had excellent bactericidal activity against penicillin-resistant pneumococci at concentrations .25 log 10 CFU/ml, respectively). Even against the quinolone-resistant strain, gemifloxacin showed good activity at concentrations above the MIC (3.9 and 4.75 log 10 CFU/ml at 5 and 10 times the MIC, respectively). The good penetration of gemifloxacin into the CSF (22 to 33%) and its efficacy in vitro and in our animal model qualify gemifloxacin as a potential therapeutic option for the treatment of meningitis, especially when resistant strains are involved. 
